Sign in
Active, not recruitingNo phase

Transcatheter Mitral Valve Replacement System (TMVR) Pilot Study and The Early Feasibility Study of the TMVR Transseptal System

Key facts

Who runs it
Medtronic Cardiovascular
Where
Ann Arbor, Atlanta, Charlottesville, Chicago, Dallas, Grand Rapids, Houston, Los Angeles, Milwaukee, Minneapolis, New York, Phoenix, Portland, St Louis, and Wormleysburg, United StatesSee the 21 sitesAlso in 6 other countries, 11 sites
Trial code
Status
Active, not recruiting
People taking part
128 people enrolled
Started
Apr 2015
Expected to end
Dec 2028
Type of study
Interventional
Treatments tested
  • Twelve TMVR Implant
  • Medtronic Intrepid™ Transcatheter Transfemoral Mitral Valve Replacement System
Record updated
14 January 2026

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 15 criteriaShow less

Who can take part

  • Severe mitral regurgitation (PILOT)
  • moderate-severe or severe mitral regurgitation (EFS)
  • Symptomatic mitral regurgitation (NYHA Class II-IV)
  • Deemed to be at high risk for conventional mitral valve surgery by the local heart team (including, at minimum, a cardiac surgeon, interventional cardiologist, and an echocardiologist) (PILOT and EFS)
  • Subjects anatomically suitable for the Intrepid TMVR delivery system, including transfemoral and transseptal access (EFS only)
  • Native mitral valve geometry and size compatible with the Intrepid™ TMVR (PILOT)

Who cannot take part

  • Prior valve surgery or need for other valve surgery
  • Prior stroke within 30 days (PILOT) or 90 days (EFS)
  • Prior myocardial infarction 90 days (EFS)
  • Gastrointestinal bleeding within 6 months (PILOT)
  • History of, or active, endocarditis if antibiotics are required (EFS)
  • Left ventricular ejection fraction (LVEF) < 20 (PILOT) or <30% (EFS)
  • Renal insufficiency; Serum Creatinine > 2.5 mg/dL (PILOT) or Creatinine Clearance <30 cc/min (EFS)
  • Evidence of intracardiac mass, thrombus, or vegetation
  • Need for coronary revascularization

Where in United States

Also in 6 other countries, 11 sites

  • University of Michigan Health System - University Hospital - PILOTAnn Arbor, United States
  • Piedmont Atlanta Hospital - PILOTAtlanta, United States
  • University of Virginia Medical Center - EFSCharlottesville, United States
  • Northwestern Memorial Hospital - PILOTChicago, United States
  • Baylor Jack and Jane Hamilton Heart and Vascular Hospital - PILOTDallas, United States
  • Corewell Health - EFSGrand Rapids, United States
  • Houston Methodist Hospital - PILOTHouston, United States
  • Cedars-Sinai Medical Center - PILOTLos Angeles, United States
  • Aurora Saint Luke's Medical Center - EFSMilwaukee, United States
  • Aurora Saint Lukes Medical Center - PILOTMilwaukee, United States
  • Abbott Northwestern Hospital - EFSMinneapolis, United States
  • Abbott Northwestern Hospital - PILOTMinneapolis, United States
  • New York-Presbyterian Hospital Columbia University Medical Center - EFSNew York, United States
  • New York-Presbyterian Hospital Columbia University Medical Center - PILOTNew York, United States
  • NYU Langone Medical Center - PILOTNew York, United States
  • The Mount Sinai Hospital (New York NY) - EFSNew York, United States
  • The Mount Sinai Hospital (New York NY) - PILOTNew York, United States
  • Abrazo Arizona Heart Hospital - EFSPhoenix, United States
  • Oregon Health & Science University Hospital - EFSPortland, United States
  • Barnes Jewish Hospital - PILOTSt Louis, United States
  • UPMC Pinnacle Harrisburg Campus - EFSWormleysburg, United States

About the trial

What the trial wants to find out

PILOT:

Read full original descriptionShow less

The study is a pilot trial to evaluate the safety and performance of the Twelve TMVR System in high risk mitral regurgitation patients.

EFS:

The study is an Early Feasibility Study to evaluate the safety and performance of the Medtronic Intrepid™ Transcatheter Mitral Valve Replacement System with Transfemoral Transseptal access in Patients with moderate-Severe or severe, Symptomatic Mitral Regurgitation

The group in the trial

  • Transcatheter Mitral Valve Replacement (TMVR) ImplantTreatment being tested

    Twelve TMVR Implant

    Treatment: Twelve TMVR Implant and Medtronic Intrepid™ Transcatheter Transfemoral Mitral Valve Replacement System

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
An Initial Evaluation of the Safety and Performance of the Transcatheter Mitral Intrepid Valve Replacement System in Patients With Severe, Symptomatic Mitral Regurgitation
Publications
Record updated
14 January 2026